It is essential that we work closer than ever before to preserve and expand access to innovative medicines and vaccines
In Conversation
We often use the term “learning and leapfrogging” in Asia-Pacific, meaning that necessity has become a mother to innovation. For example, the rapid adoption of digital…
Although we have been far away from our partners during the COVID-19 pandemic considering the travel bans in place, I actually feel that we have never…
The traditional bulk analysis method is well-established and suited for diseases that are more homogenous, but cancer and some types of autoimmune diseases are well-known for…
I am optimistic because more people, therapies and medicines are being added [to the Dominican Republic's social security program] and the system has not broken the…
We are the only company that digitizes stain-free biopsies, using our proprietary biophotonics technology and platform for stain-free AI-based digital pathology. This is a huge differentiator
There is a huge interest now for healthcare data analysis to better protect people from the effects of the [corona]virus. This is really opening new doors,…
The idea of CIRM was – and continues to be – the building of a regenerative medicine ecosystem in California for vital research opportunities to address…
As insurers, we want to see fair and affordable pricing, and we are willing to pay the “right price” for the right therapies that bring value…
Europe has the tools to advance in both basic and translational research but on the latter, it perhaps needs to simplify its processes and expand both…
We have a very strong R&D team at ADC Therapeutics that has been able to file – on average – two INDs per year since 2012
I predict that we will observe [pharma] manufacturing coming back to Europe, and Ticino will play a role in that
